Intuitive Surgical’s da Vinci 5 surgical platform, which began shipping in earnest on April 1, 2026, runs on 10,000 times the computing power of the da Vinci Xi and was co-engineered with NVIDIA’s Isaac platform. That is a working hospital robot, on the floor, today, that needed an AI compute stack nobody had five years ago. Meanwhile, IBM, Google, and startups are pushing logical qubit counts past the threshold where useful chemistry and optimization workloads stop being theoretical. The machine intelligence buildout is no longer a venture conference pitch.
Three ETFs give you clean exposure to this shift without forcing you to pick the one quantum startup that survives or the single robotics vendor that wins. The Defiance Quantum ETF (NYSEARCA:QTUM) targets quantum computing and machine learning hardware. The Global X Robotics & Artificial Intelligence ETF (NASDAQ:BOTZ | BOTZ Price Prediction) concentrates on established robotics and AI leaders. The ROBO Global Robotics and Automation Index ETF (NYSEARCA:ROBO) takes the broadest cut, including the picks-and-shovels chip and test-equipment names that the others underweight.
Why this is moving faster than consensus thinks
Most investors believe quantum is a decade away and robotics is a Japanese industrial trade. Both views are stale. Johnson & Johnson MedTech is building surgical robotics on NVIDIA’s Isaac platform, GE HealthCare is integrating NVIDIA compute into CT, PET, cardiac, mammography, and ultrasound systems, and Corning signed a multiyear deal with NVIDIA on optical connectivity targeting a $20 billion annualized sales run rate by the end of 2026. The industrial robotics market is on track for roughly roughly $80 billion by 2029, with global service robots pushing toward $84.8 billion by 2028. None of those numbers require a quantum breakthrough. The quantum optionality sits on top of that.
QTUM: the cleanest quantum and ML hardware bet
QTUM is the only one of the three with quantum computing in its mandate. The fund tracks the BlueStar Quantum Computing and Machine Learning Index and equal-weights holdings across companies doing quantum R&D, advanced semiconductors, and ML hardware and software. Equal weighting matters here. In a theme where the eventual winner is genuinely unknown, holding 70-odd names at similar weights keeps a single failed pure-play from sinking the fund and prevents NVIDIA from quietly becoming half the portfolio the way it would in a cap-weighted index.
QTUM is up about 29% year to date and roughly 68% over the past year, with a five-year return north of 218%. The expense ratio sits at 0.40%, reasonable for an index this niche. The tradeoff is straightforward: this is the most narrative-driven of the three. If quantum commercialization slips by another three to five years, QTUM will trade like a high-beta semiconductor proxy. That means part of what you are paying for is optionality on a timeline that nobody can pin down.
BOTZ: concentrated exposure to robotics blue chips
BOTZ runs a much tighter portfolio than QTUM or ROBO. Net assets sit at roughly $3.5 billion, and the top five names control more than 40% of the fund:
- ABB — about 11%
- NVIDIA — 10%
- FANUC — 10%
- Keyence — 6%
- Intuitive Surgical — 6%
If you want concentrated exposure to established global champions in industrial automation, factory vision systems, and surgical robotics, this is the cleanest vehicle.
The Japanese tilt is a structural feature. FANUC, Keyence, Daifuku, SMC, OMRON, and YASKAWA represent a meaningful chunk and give exposure to the factory automation upgrade cycle running through Japanese capital equipment. Layered on top, NVIDIA and Intuitive Surgical capture the AI compute and surgical robot end-market simultaneously, the combination that produced the da Vinci 5 launch.
Concentration is showing up in recent returns. BOTZ is up only about 7% year to date and 26% over the past year, with a five-year return of roughly 20%. Intuitive Surgical alone has been volatile: the stock sold off in April 2026 despite a Q1 earnings beat and a raised full-year guide, and BTIG cut its price target from $616 to $574 citing CMS payment rule changes. When the top names move together, BOTZ moves with them.
ROBO: the broader picks-and-shovels pick
ROBO is the one most investors skip past, and it probably deserves the most attention right now. The fund uses tiered weighting that distinguishes pure-play robotics and automation companies from those with partial exposure, spreading across roughly 75 to 80 names. The top of the book leans into the semiconductor and test-equipment layer that makes robotics and AI work: Intel at about 9%, Advantest at 6%, AMD at 6%, KLA at 4%, and Teradyne at 4%. NVIDIA sits at only about 3%, a fraction of its weight in BOTZ.
That positioning is the entire investment case. ROBO captures the enabling layer (chips, lithography test, motion control) alongside robotics end markets in healthcare, warehouse automation, and precision agriculture. The expense ratio matches QTUM at 0.40%. Performance has kept pace: the fund is up around 19% year to date, with a 47% one-year return that beats BOTZ and a ten-year track record of roughly 247%. The semiconductor weighting means ROBO will trade more like a chip index in a downcycle than a pure robotics fund, a feature in a buildout cycle and a bug when capex rolls over.
How to choose between them
QTUM is right if you specifically want quantum and ML hardware optionality and are prepared to wait. The equal-weight structure and genuine quantum exposure are unique among large thematic ETFs. If quantum slips, you still own a diversified deep-tech basket. If it works, this is the cleanest way to be early.
BOTZ fits the investor who wants concentrated, high-conviction exposure to established robotics and AI leaders and is comfortable with a portfolio where five names drive the outcome. It is the most direct way to own the NVIDIA-plus-Japanese-automation thesis. Recent underperformance versus QTUM and ROBO is the price of concentration and will reverse if Intuitive Surgical and Japanese automation names regain leadership.
ROBO is the contrarian default. It is older, broader, and tilted toward the semiconductor and test-equipment layer that every robotics and AI buildout must run on. For an investor who wants robotics and automation exposure without betting on which end-market vendor wins, ROBO is the most defensible vehicle. The primary risks across all three are the same: quantum timelines are genuinely uncertain, and commoditization in industrial arms and warehouse systems remains the bear case worth tracking.
Top Gaining Stocks
Top Losing Stocks